625394-65-2

Basic information

• Product Name: 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine
• Synonyms: 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine;2H-1,4-Benzoxazine, 8-broMo-3,4-dihydro-
• CAS NO: 625394-65-2
• Molecular Formula: C8H8BrNO
• Molecular Weight: 214.06
• Mol File: 625394-65-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 299.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.534±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.56±0.20(Predicted)
• CAS DataBase Reference: 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine(625394-65-2)
• EPA Substance Registry System: 8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine(625394-65-2)

Safety Data

• Hazardous Substances Data: 625394-65-2(Hazardous Substances Data)

Usage

General Description

8-Bromo-3,4-dihydro-2H-benzo[1,4]oxazine, also known as Brombenzoxazine, is a chemical compound with the molecular formula C8H8BrNO. It is a heterocyclic compound that contains a bromine atom and a nitrogen atom in its structure. Brombenzoxazine is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential use as a ligand in organic synthesis and catalysis. The compound is known for its ability to undergo various chemical reactions, including, but not limited to, nucleophilic aromatic substitution and Suzuki-Miyaura coupling. Additionally, Brombenzoxazine has been investigated for its potential biological activities and pharmacological properties.

Upstream product

• 28165-50-6 2-amino-6-bromophenol 
• 688363-48-6 8-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 625394-74-3 2-(2,6-dibromo-phenoxy)ethylamine 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 
• 106-93-4 ethylene dibromide 

Downstream Products

• 625394-66-3 8-bromo-3,4-dihydro-2H-benzo[1,4]oxazine, hydrochloride salt 

Relevant articles and documents

HETEROCYCLE CDK INHIBITORS AND THEIR USE THEREOF

The disclosure is directed to, in part, to heterocycle CDK inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

NOVEL COMPOUNDS

The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin spec

NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.